Alopecia
Conditions
Brief summary
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
Interventions
Setipiprant tablets, orally, BID for 24 weeks.
Placebo tablets, orally, BID for 24 weeks.
Finasteride tablet, orally, once daily for 24 weeks.
Sponsors
Study design
Eligibility
Inclusion criteria
* Participant has androgenetic alopecia (AGA) * Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.
Exclusion criteria
* History of hair loss for reasons other than AGA * Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft * Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth * Hair-weaving within 6 months * Use of hair colorants or dyes within 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Target Area Hair Count (TAHC) at Week 24 | Baseline (Day 1) to Week 24 | TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method. |
| Subject Self-Assessment (SSA) Score in Hair Growth at Week 24 | Week 24 | The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Two placebo tablets BID at 12-hour intervals for 24 weeks. | 70 |
| Setipiprant Setipiprant 1000 mg (2 X 500 mg) tablets, orally, BID at 12-hour intervals for 24 weeks. | 78 |
| Finasteride Finasteride 1 mg tablet, orally, once daily for 24 weeks. | 11 |
| Total | 159 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 2 | 6 | 1 |
| Overall Study | Lost to Follow-up | 11 | 8 | 1 |
| Overall Study | Non-Compliance with Study Drug | 2 | 0 | 0 |
| Overall Study | Withdrawal of Consent | 11 | 12 | 2 |
Baseline characteristics
| Characteristic | Placebo | Setipiprant | Finasteride | Total |
|---|---|---|---|---|
| Age, Continuous | 36.9 years STANDARD_DEVIATION 6.08 | 36.3 years STANDARD_DEVIATION 6.69 | 34.1 years STANDARD_DEVIATION 3.05 | 36.4 years STANDARD_DEVIATION 6.25 |
| Race/Ethnicity, Customized American Indian or Alaska Native | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Asian | 4 Participants | 1 Participants | 1 Participants | 6 Participants |
| Race/Ethnicity, Customized Black or African American | 4 Participants | 3 Participants | 0 Participants | 7 Participants |
| Race/Ethnicity, Customized Hispanic | 6 Participants | 8 Participants | 0 Participants | 14 Participants |
| Race/Ethnicity, Customized Missing | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Native Hawaiian or Other Pacific Islander | 2 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized Non-hispanic | 64 Participants | 70 Participants | 11 Participants | 145 Participants |
| Race/Ethnicity, Customized Other | 1 Participants | 2 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White | 59 Participants | 70 Participants | 9 Participants | 138 Participants |
| Sex/Gender, Customized Male | 70 Participants | 78 Participants | 11 Participants | 159 Participants |
| Target Area Hair Count (TAHC) Within Left 1 cm^2 Circular Area | 136.7 terminal hairs/cm^2 STANDARD_DEVIATION 55.81 | 148.6 terminal hairs/cm^2 STANDARD_DEVIATION 64.58 | 139.9 terminal hairs/cm^2 STANDARD_DEVIATION 47.72 | 142.8 terminal hairs/cm^2 STANDARD_DEVIATION 59.67 |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 73 | 0 / 81 | 0 / 12 |
| other Total, other adverse events | 26 / 73 | 28 / 81 | 6 / 12 |
| serious Total, serious adverse events | 2 / 73 | 0 / 81 | 0 / 12 |
Outcome results
Change From Baseline in Target Area Hair Count (TAHC) at Week 24
TAHC was measured using digital imaging analysis and was reported in terminal hairs/centimeters square (cm\^2). TAHC is a standardized objective quantification of the number of hairs within a prespecified target area of the scalp at different timepoints, using macrophotography digital images. The total number of terminal hairs (hair width ≥ 30 μm) was calculated from macrophotographs. The target area used to count TAHC was a 1 cm\^2 circular area of clipped hair (length approximately 1 mm) located at the anterior leading edge of the vertex thinning area of the scalp and centered with a semi-permanent microdot tattoo to ensure the same target area was reproduced at each visit. A positive change from Baseline indicated improvement (increase in the number of terminal hairs). Missing data are imputed up to Week 24 using last observation carried forward (LOCF) method.
Time frame: Baseline (Day 1) to Week 24
Population: mITT population included all randomized participants who received study intervention and had a baseline and at least 1 postbaseline measurement for 1 of the coprimary efficacy measures. As per protocol Amendment 1, Finasteride arm group was not included in the analysis model. Number analyzed is participants with data available for analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Target Area Hair Count (TAHC) at Week 24 | 6.7 terminal hairs/cm^2 | Standard Error 3.25 |
| Setipiprant | Change From Baseline in Target Area Hair Count (TAHC) at Week 24 | 7.1 terminal hairs/cm^2 | Standard Error 3.03 |
Subject Self-Assessment (SSA) Score in Hair Growth at Week 24
The SSA consisted of a single-item measure that assesses each participant's perception of change in scalp hair growth. The participant used a standardized global photograph of his scalp taken at the Screening visit presented side by side with a standardized global photograph taken at the postbaseline visit to give a comparative score. The photographs were presented in a blinded and randomized manner to avoid influencing the participant, and response options were on a 7-point ordinal scale (where, -3=Greatly decreased, -2=Moderately decreased, -1=Slightly decreased, 0=No change, +1=Slightly increased, +2=Moderately increased and +3=Greatly increased). The higher the mean SSA value, the more the perception of hair growth from baseline. Missing data are imputed up to Week 24 using LOCF method.
Time frame: Week 24
Population: mITT population included all randomized participants who received study intervention and had a baseline and at least 1 postbaseline measurement for 1 of the coprimary efficacy measures. As per protocol Amendment 1, Finasteride arm group was not included in the analysis model. Number analyzed is participants with data available for analysis.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Subject Self-Assessment (SSA) Score in Hair Growth at Week 24 | -0.2 score on a scale | Standard Error 0.15 |
| Setipiprant | Subject Self-Assessment (SSA) Score in Hair Growth at Week 24 | -0.3 score on a scale | Standard Error 0.14 |